Healthcare Industry News: gene therapy
News Release - April 16, 2007
Alba Therapeutics Announces Appointment of Chief Financial OfficerBALTIMORE, April 16 (HSMN NewsFeed) -- Alba Therapeutics Corporation today announced the appointment of Jeffrey W. Church as its Chief Financial Officer, effective April 23, 2007.
"We are very pleased to announce the appointment of Jeff as our Chief Financial Officer," said Blake Paterson, M.D., Chief Executive Officer of Alba Therapeutics. "We are in the midst of an exciting growth phase, and Jeff's extensive financial, operational and management experience will be a valuable addition to our team." Mr. Church commented, "I am excited to join Alba and look forward to working with the management team to achieve the Company's strategic goals. Alba's technology and clinical stage assets offer a tremendous opportunity to build a strong commercial organization and specialty pharmaceutical company."
Prior to joining Alba, Mr. Church held senior financial executive positions with several clinical stage biotech and medical device companies. From 2006 to April 2007, Mr. Church was Vice President, CFO, Treasurer and Corporate Secretary of Novavax, Inc., an early stage vaccine development company. From 1998 to 2006, Mr. Church served as CFO, Treasurer and Corporate Secretary for GenVec, Inc., a clinical-stage gene therapy company. While at GenVec, he raised over $150 million in equity, debt and facilities financing, including a successful IPO in December 2000. Prior to GenVec, Mr. Church was Executive Vice President, CFO and Director of Biospherics, Inc. (now Spherix), where he directed a team of 250 professionals in sales and marketing, technical services and financial operations. From 1986 to 1996, Mr. Church served as Senior Vice President of Finance and CFO for Meridian Medical Technologies, Inc., where he helped transform Meridian from an unprofitable defense contractor to a profitable medical device company through the creation of a novel base maintenance contract with the U.S. Department of Defense and the introduction and supply of the EpiPenŽ auto-injector. Meridian was subsequently acquired by King Pharmaceutical for $250 million. Mr. Church started his career in 1979 with the international public accounting firm, Price Waterhouse, advancing to the level of Audit Manager.
Mr. Church holds a B.S. degree, summa cum laude, from the University of Maryland and received his Maryland Certified Public Accountant accreditation in 1979.
Alba Therapeutics Corporation is a privately held biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to commercializing disease-modifying therapeutics and vaccine and drug delivery adjuvant based regulation of the barrier function, tight junctions and the zonulin pathway. Alba's lead compound, AT-1001, is targeted towards the treatment of Celiac Disease, Inflammatory Bowel Disease and Type 1 Diabetes.
Source: Alba Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.